Zhongzhi Pharmaceutical Holdings Limited provided consolidated earnings guidance for the year ended 31 December 2023. for the year,it is expected that Group will record a significant increase in the net profit of the Group for Fiscal Year 2023 by more than 50% as compared to the audited net profit of the Group for the correspondence period in 2022. The expected increase in the net profit of the Group for FY2023 is mainly attributable to a significant increase in the revenue generated from the Chinese patented medicines segment of the Group attributable to continued demands for the Chinese patented medicines products.